Anhydrohazuntiphyllidine






Names

    • Anhydrohazuntiphyllidine

Attributes

  • Canonical SMILES

    CC[C@]34C[C@](CN8C7=C(C%13)C[C@@]%11(CC)C%10[C@](CCN%10C[C@@H]%12[C@H]%11O%12)7C9=C8C=CC=C9)%13C([C@]62C3N(CC6)C[C@@H]5[C@H]4O5)=NC1=C2C=CC=C1

  • InChI

    InChI=1S/C40H44N4O2/c1-3-37-18-23-17-36(22-44-27-12-8-6-10-25(27)39(30(23)44)13-15-42(34(37)39)19-28-31(37)45-28)21-38(4-2)32-29(46-32)20-43-16-14-40(35(38)43)24-9-5-7-11-26(24)41-33(36)40/h5-12,28-29,31-32,34-35H,3-4,13-22H2,1-2H3/t28-,29-,31-,32-,34?,35?,36+,37-,38-,39+,40+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 47.14
  • #RotBonds: 2
  • MW: 612.8180000000002
  • HBD: 0
  • HBA: 6
  • logP: 5.723500000000007
  • Chemical Formula: C40H44N4O2


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. pachysiphon Nigeria, Netherlands 403125 HXJ20171220

External Databases


References

  • Tabernaesines A-I, Cytotoxic Aspidosperma-Aspidosperma-Type Bisindole Alkaloids from Tabernaemontana pachysiphon. J Nat Prod, 2020 (PMID 33112136).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Cytotoxicity

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -5.04
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Non-Absorbed
    Madin-Darby Canine Kidney -0.41
    Human Oral Bioavailability 50% Bioavailable
    P-Glycoprotein Inhibitor Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 627.88
    Distribution Blood-Brain Barrier (Central Nervous System) -2.34
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.2
    Plasma Protein Binding 54.79
    Steady State Volume of Distribution 1.81
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 8.22
    Organic Cation Transporter 2 Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Toxic
    Bee Toxic
    Bioconcentration Factor -13.96
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.91
    Liver Injury II Safe
    hERG Blockers Safe
    Daphnia Maga 6.74
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Toxic
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Toxic
    T. Pyriformis -1143892.7
    Rat (Acute) 3.25
    Rat (Chronic Oral) 0.66
    Fathead Minnow 1445.31
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Toxic
    General Properties Boiling Point 126714.08
    Hydration Free Energy -2.92
    Log(D) at pH=7.4 4.08
    Log(P) 4.33
    Log S -4.91
    Log(Vapor Pressure) -4089.37
    Melting Point 233.18
    pKa Acid -6.76
    pKa Basic 6.23